Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children

This publication has 11 references indexed in Scilit:

• Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity
  Clinical Infectious Diseases, 2000
• Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults
  Antimicrobial Agents and Chemotherapy, 1999
• Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy
  AIDS, 1999
• Indinavir Concentrations and Antiviral Effect
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
• Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
  Clinical Pharmacokinetics, 1999
• Pharmacokinetic Drug-Drug Interaction Study of Delavirdine and Indinavir in Healthy Volunteers
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
• Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
  Antimicrobial Agents and Chemotherapy, 1997
• A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.
  Journal of Pharmacokinetics and Biopharmaceutics, 1997
• A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
  AIDS, 1996
• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
  Antiviral Research, 1996